{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:42Z","timestamp":1787070942663,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Urinary cell-free deoxyribonucleic acid (DNA) (ucfDNA) holds promise as a biomarker; however, its potential remains largely unexplored. We examined the fragmentation pattern of ucfDNA and identified somatic mutations within urine samples from metastatic breast cancer (MBC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Urine and blood specimens were collected before treatment from 45 MBC patients and posttreatment urine samples from 16 of the 45 patients at the China National Cancer Center. Somatic mutations and tumor mutational burden (TMB) in the urine and plasma of 10 patients were analyzed by next-generation sequencing (NGS). Fragmentation patterns of cfDNA were displayed using electropherograms. Differences in the extracted amount of cfDNA, length of cfDNA fragments, and TMB between urine and plasma were compared using a Wilcoxon test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The fragmentation patterns of ucfDNA were categorized as follows: (1) profile A (n = 26) containing a short peak (100\u2013200 bp) and a long peak (&gt;1500 bp); (2) profile B (n = 8) containing only a long peak; and (3) profile C (n = 11) containing flat pattern. For profile A patients, the short-peaked ucfDNA circulating in the bloodstream was much shorter compared with plasma cfDNA (149 vs. 171 bp, Wilcoxon test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023). The fragmentation patterns in lung metastasis patients exhibited a higher propensity toward profile C (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002). After treatment, 87.5% of the patients exhibited consistent fragmentation patterns. The concordance rate for somatic mutations in the plasma and urine was 30%, and the median TMB of urine and plasma was not significantly different.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study established a fragmentation pattern for ucfDNA and detected somatic mutations in the urine of MBC patients. These results suggest the potential application of ucfDNA as a biomarker for MBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1359_23","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T03:00:43Z","timestamp":1709866843000},"page":"563-569","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Fragmentation patterns of cell-free DNA and somatic mutations in the urine of metastatic breast cancer patients"],"prefix":"10.4103","volume":"20","author":[{"given":"Shaoyan","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4103\/jcrt.jcrt_1095_21","article-title":"Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer:A systematic review and meta-analysis","volume":"18","author":"Yeh","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"244","DOI":"10.6061\/clinics\/2017(04)09","article-title":"Breast cancer screening in developing countries","volume":"72","author":"da Costa Vieira","year":"2017","journal-title":"Clinics (Sao Paulo)"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.4103\/jcrt.JCRT_415_20","article-title":"A study for evaluating clinical relevance of circulating cell-free DNA in cervical cancer","volume":"18","author":"Shrivastava","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/gtmb.2018.0189","article-title":"Urine-based liquid biopsy for nonurological cancers","volume":"23","author":"Jain","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/clinchem\/46.8.1078","article-title":"Genetic analysis of DNA excreted in urine:A new approach for detecting specific genomic DNA sequences from cells dying in an organism","volume":"46","author":"Botezatu","year":"2000","journal-title":"Clin Chem"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14737159.2016.1254551","article-title":"The potential use of urine cell free DNA as a marker for cancer","volume":"16","author":"Salvi","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1525-1578(10)60497-7","article-title":"Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer","volume":"6","author":"Su","year":"2004","journal-title":"J Mol Diagn"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1196\/annals.1318.014","article-title":"Transrenal DNA as a diagnostic tool:Important technical notes","volume":"1022","author":"Su","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"574120","DOI":"10.1155\/2015\/574120","article-title":"Urine cell-free DNA integrity analysis for early detection of prostate cancer patients","volume":"2015","author":"Salvi","year":"2015","journal-title":"Dis Markers"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG Plus PCA3 for individualized prostate cancer risk assessment","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur Urol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4103\/jcrt.jcrt_1014_21","article-title":"Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer","volume":"19","author":"Zaidi","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.32607\/20758251-2015-7-3-48-54","article-title":"Extracellular nucleic acids in urine:Sources, structure, diagnostic potential","volume":"7","author":"Bryzgunova","year":"2015","journal-title":"Acta Naturae"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3233\/CBM-140407","article-title":"Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA","volume":"14","author":"Ghanjati","year":"2014","journal-title":"Cancer Biomark"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.gene.2016.06.033","article-title":"Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva:A qualitative study","volume":"590","author":"Yao","year":"2016","journal-title":"Gene"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-16-2592","article-title":"Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers","volume":"23","author":"Fujii","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","article-title":"A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma","volume":"11","author":"Reckamp","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4103\/jcrt.JCRT_99_20","article-title":"Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung:Study in a tertiary care hospital","volume":"17","author":"Ghosh","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1016\/j.ejso.2021.07.017","article-title":"Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer","volume":"47","author":"Ohta","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/annonc\/mdx095","article-title":"Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor","volume":"28","author":"Siravegna","year":"2017","journal-title":"Ann Oncol"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12094-016-1534-9","article-title":"Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs","volume":"19","author":"Chen","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.20517\/2394-5079.2017.15","article-title":"Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma","volume":"3","author":"Hann","year":"2017","journal-title":"Hepatoma Res"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41551-021-00837-3","article-title":"Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics","volume":"6","author":"Song","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"(Suppl 1)","key":"R24-20241021","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.4103\/jcrt.jcrt_384_22","article-title":"The issues and challenges with cancer biomarkers","volume":"19","author":"Purkayastha","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"eaaw3616","DOI":"10.1126\/science.aaw3616","article-title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","volume":"372","author":"Lo","year":"2021","journal-title":"Science"},{"issue":"(Suppl 13)","key":"R26-20241021","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-2164-16-S13-S1","article-title":"Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation","volume":"16","author":"Ivanov","year":"2015","journal-title":"BMC Genomics"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat Commun"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.32308","article-title":"Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12920-015-0107-z","article-title":"High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA","volume":"8","author":"Chandrananda","year":"2015","journal-title":"BMC Med Genomics"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.molmed.2020.01.012","article-title":"Cell-free DNA and apoptosis:How dead cells inform about the living","volume":"26","author":"Heitzer","year":"2020","journal-title":"Trends Mol Med"},{"key":"R31-20241021","doi-asserted-by":"crossref","first-page":"e1500587","DOI":"10.1126\/sciadv.1500587","article-title":"Replicating nucleosomes","volume":"1","author":"Ramachandran","year":"2015","journal-title":"Sci Adv"},{"key":"R32-20241021","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.bdq.2019.100087","article-title":"The emerging role of cell-free DNA as a molecular marker for cancer management","volume":"17","author":"Bronkhorst","year":"2019","journal-title":"Biomol Detect Quantif"},{"key":"R33-20241021","doi-asserted-by":"crossref","first-page":"eaaz3088","DOI":"10.1126\/scitranslmed.aaz3088","article-title":"Analysis of recurrently protected genomic regions in cell-free DNA found in urine","volume":"13","author":"Markus","year":"2021","journal-title":"Sci Transl Med"},{"key":"R34-20241021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age:Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R35-20241021","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"R36-20241021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"R37-20241021","doi-asserted-by":"crossref","first-page":"e12881","DOI":"10.15252\/emmm.202012881","article-title":"Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients","volume":"13","author":"Mouliere","year":"2021","journal-title":"EMBO Mol Med"},{"key":"R38-20241021","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1002\/cam4.3236","article-title":"Assessment of somatic mutations in urine and plasma of Wilms tumor patients","volume":"9","author":"Miguez","year":"2020","journal-title":"Cancer Med"},{"key":"R39-20241021","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.tranon.2018.08.006","article-title":"Somatic TP53 mutations are detectable in circulating tumor DNA from children with anaplastic wilms tumors","volume":"11","author":"Treger","year":"2018","journal-title":"Transl Oncol"},{"key":"R40-20241021","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","article-title":"Oxidative DNA damage:Mechanisms, mutation, and disease","volume":"17","author":"Cooke","year":"2003","journal-title":"Faseb J"},{"key":"R41-20241021","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"R42-20241021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.gde.2017.01.017","article-title":"Epigenome-wide association studies for cancer biomarker discovery in circulating cell-free DNA:Technical advances and challenges","volume":"42","author":"Tani\u0107","year":"2017","journal-title":"Curr Opin Genet Dev"},{"key":"R43-20241021","doi-asserted-by":"crossref","first-page":"916725","DOI":"10.3389\/fcell.2022.916725","article-title":"DNMT3A and DNMT3B in breast tumorigenesis and potential therapy","volume":"10","author":"Man","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"R44-20241021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.21037\/atm-20-2137","article-title":"DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis","volume":"9","author":"Rong","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1359_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:20Z","timestamp":1787067560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1359_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1359_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"2023-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}